Top Markets
Coin of the day
Chinook Therapeutics, Inc. Chinook Therapeutics, Inc.

Chinook Therapeutics, Inc.

KDNY
Rankning i aktier #7142
Chinook Therapeutics, Inc., a biotechnology enterprise in the clinical... Chinook Therapeutics, Inc., a biotechnology enterprise in the clinical development phase, is dedicated to the identification, progression, and market introduction of precise medical treatments for kidney-related conditions. The company's primary therapeutic candidate, atrasentan, is an endothelin receptor antagonist currently in Phase III clinical trials. This drug aims to treat IgA nephropathy and various other glomerular diseases characterized by proteinuria. Beyond its lead program, Chinook's investigational pipeline includes BION-1301, an anti-APRIL monoclonal antibody, which is presently being evaluated in a Phase I/II study for IgA nephropathy. Another promising candidate is CHK-336, an oral small molecule designed to inhibit LDHA, intended for patients with primary hyperoxaluria. The firm also maintains active research initiatives exploring solutions for other uncommon and severe chronic kidney ailments. Chinook Therapeutics, Inc. is based in Seattle, Washington.
Aktiekurs
$40.39
Senast synkroniserad: 2023-08-18
Marknadsvärde
$1.70B
Förändring (1 dag)
0.00%
Förändring (1 år)
0.00%
Land
US
Handel Chinook Therapeutics, Inc. (KDNY)

Kategori

Historik för aktiesplit för Chinook Therapeutics, Inc. (KDNY)
Aktien Chinook Therapeutics, Inc. (symbol: KDNY) har genomgått totalt 0 aktiesplitar.
Den senaste spliten skedde den Aug 28, 2026.
En KDNY-aktie köpt före Aug 28, 2026 motsvarar nu 0 KDNY-aktier.
Lista över aktiesplitar
År Split Multipel Kumulativ multipel
Inte tillräckligt med data för de angivna datumen.
Aktiesplitar för liknande företag eller konkurrenter
Företag Antal aktiesplitar Kumulativ multipel Land
1 x2
US
0 -
NL
1 x3
AU
0 -
US
0 -
CH